RCKT•benzinga•May 27, 2025 at 11:15 AM

Rocket Pharmaceuticals Says Patient In Phase 2 Trial Of RP-A501 Experienced Serious Adverse Event And Has Since Passed; Co. Voluntarily Paused Further Dosing In The Study On May 23

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 27, 2025 by benzinga